DIADEMA PARTNERS LP
Reported holdings as of Q2 2026, from 7 quarterly filings.
This filer last reported in Q2 2026; the most recent quarter on file across all filers is Q3 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.
Holdings
Download these holdings as CSV
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| ABIVAX SA CALL+PUT | ABVX | $101.8M | 163,644 | +7.67pp | 4q | +115.5%+$54.5M | |
| VIKING THERAPEUTICS INC CALL+PUT | VKTX | $78.5M | 441,808 | +3.37pp | 6q | -15.9%-$14.8M | |
| BRISTOL-MYERS SQUIBB CO CALL+PUT | BMY | $53.6M | options only | - | new | OPTIONS | |
| UNITED THERAPEUTICS CORP DEL | UTHR | $28.7M | 52,989 | -5.20pp | 3q | +94.1%+$13.9M | |
| REVOLUTION MEDICINES INC | RVMD | $26.1M | 139,218 | -0.12pp | 5q | +72.1%+$10.9M | |
| UNIQURE NV CALL+PUT | QURE | $24.6M | options only | +1.50pp | 7q | OPTIONS | |
| NOVARTIS AG CALL+PUT | NVS | $23.5M | options only | - | new | OPTIONS | |
| KODIAK SCIENCES INC CALL+PUT | KOD | $21.9M | 218,117 | -0.09pp | 4q | +13.0%+$2.5M | |
| CAPRICOR THERAPEUTICS INC CALL+PUT | CAPR | $20.8M | options only | -2.71pp | 7q | OPTIONS | |
| COGENT BIOSCIENCES INC | COGT | $19.1M | 493,664 | +0.30pp | 7q | +52.9%+$6.6M | |
| BRIDGEBIO PHARMA INC | $18.6M | 250,000 | -0.81pp | 2q | DEBT | ||
| CORCEPT THERAPEUTICS INC CALL | CORT | $17.9M | options only | +1.11pp | 6q | OPTIONS | |
| BIOMARIN PHARMACEUTICAL INC | BMRN | $17.9M | 312,846 | +0.84pp | 6q | +111.1%+$9.4M | |
| KYMERA THERAPEUTICS INC CALL | KYMR | $17.2M | options only | - | new | OPTIONS | |
| SUMMIT THERAPEUTICS INC CALL+PUT | SMMT | $16.3M | 60,000 | - | new | NEW | |
| HIMS & HERS HEALTH INC CALL+PUT | HIMS | $13.6M | options only | - | new | OPTIONS | |
| REPLIMUNE GROUP INC CALL+PUT | REPL | $13.3M | options only | +0.68pp | 7q | OPTIONS | |
| BIOGEN INC CALL | BIIB | $13.0M | options only | - | new | OPTIONS | |
| ELI LILLY & CO PUT | LLY | $12.0M | options only | +0.58pp | 6q | OPTIONS | |
| INCYTE CORP PUT | INCY | $11.9M | options only | -1.43pp | 4q | OPTIONS | |
| EDGEWISE THERAPEUTICS INC | EWTX | $11.1M | 272,214 | +0.26pp | 3q | HELD | |
| ARCUS BIOSCIENCES INC CALL | RCUS | $10.7M | 223,810 | +0.48pp | 2q | -6.0%-$686.7K | |
| BIONTECH SE CALL | BNTX | $9.3M | options only | - | new | OPTIONS | |
| CORBUS PHARMACEUTICALS HLDGS CALL | CRBP | $8.8M | 301,264 | +0.22pp | 2q | -31.5%-$4.0M | |
| VAXCYTE INC CALL+PUT | PCVX | $8.5M | 45,071 | +0.31pp | 7q | +79.8%+$3.8M | |
| BIOAGE LABS INC CALL | BIOA | $8.5M | 146,334 | +0.89pp | 3q | +143.9%+$5.0M | |
| IMMUNOCORE HLDGS PLC | IMCR | $8.1M | 254,863 | +0.03pp | 6q | +31.9%+$2.0M | |
| 4D MOLECULAR THERAPEUTICS IN | FDMT | $7.6M | 571,107 | - | new | NEW | |
| NOVO-NORDISK A S PUT | NVO | $7.5M | 100,000 | +0.51pp | 6q | +586.0%+$6.4M | |
| SELLAS LIFE SCIENCES GROUP I CALL+PUT | SLS | $7.4M | options only | +0.72pp | 5q | OPTIONS | |
| MODERNA INC PUT | MRNA | $7.0M | options only | -0.49pp | 2q | OPTIONS | |
| CORVUS PHARMACEUTICALS INC CALL | CRVS | $6.4M | 294,811 | -0.07pp | 4q | +20.4%+$1.1M | |
| MONTE ROSA THERAPEUTICS INC CALL | GLUE | $6.0M | 78,391 | +0.24pp | 3q | -58.1%-$8.4M | |
| ALUMIS INC CALL | ALMS | $5.6M | options only | +0.22pp | 2q | OPTIONS | |
| ROYALTY PHARMA PLC CALL | RPRX | $5.6M | options only | - | new | OPTIONS | |
| JOHNSON & JOHNSON | JNJ | $5.6M | 22,000 | -1.53pp | 3q | -59.1%-$8.1M | |
| UNICYCIVE THERAPEUTICS INC CALL | UNCY | $5.1M | 303,676 | +0.53pp | 2q | +186.3%+$3.3M | |
| CELLDEX THERAPEUTICS INC NEW CALL+PUT | CLDX | $5.1M | options only | - | new | OPTIONS | |
| BIOHAVEN LTD CALL | BHVN | $4.7M | options only | +0.14pp | 3q | OPTIONS | |
| VERA THERAPEUTICS INC PUT | VERA | $4.6M | 57,608 | - | new | NEW | |
| TENAX THERAPEUTICS INC CALL | TENX | $4.5M | options only | +0.08pp | 3q | OPTIONS | |
| RELAY THERAPEUTICS INC | RLAY | $4.3M | 230,677 | - | new | NEW | |
| TG THERAPEUTICS INC CALL | TGTX | $4.2M | options only | -0.64pp | 7q | OPTIONS | |
| AMGEN INC CALL | AMGN | $3.8M | 102,701 | - | new | NEW | |
| ZYMEWORKS INC | ZYME | $3.7M | 142,132 | -0.14pp | 6q | HELD | |
| TAYSHA GENE THERAPIES INC | TSHA | $3.6M | 522,619 | - | new | NEW | |
| INTELLIA THERAPEUTICS INC CALL | NTLA | $3.4M | options only | -0.01pp | 4q | OPTIONS | |
| NURIX THERAPEUTICS INC | NRIX | $2.9M | 121,539 | - | new | NEW | |
| INDIVIOR PHARMACEUTICALS INC | INDV | $2.8M | 67,512 | -0.02pp | 2q | -5.4%-$158.5K | |
| INVENTIVA SA | IVA | $2.7M | 740,786 | +0.02pp | 3q | +110.2%+$1.4M | |
| ORUKA THERAPEUTICS INC | ORKA | $2.6M | 27,799 | - | new | NEW | |
| CYTOKINETICS INC PUT | CYTK | $2.6M | options only | -2.48pp | 2q | OPTIONS | |
| RELMADA THERAPEUTICS INC | RLMD | $2.5M | 361,367 | +0.08pp | 3q | +79.9%+$1.1M | |
| ANNEXON INC CALL | ANNX | $2.2M | 27,516 | -0.18pp | 3q | -79.3%-$8.3M | |
| CELCUITY INC CALL | CELC | $2.1M | options only | -0.18pp | 2q | OPTIONS | |
| SEPTERNA INC PUT | SEPN | $2.0M | options only | +0.25pp | 2q | OPTIONS | |
| CYBIN INC CALL | HELP | $2.0M | 200,000 | - | new | NEW | |
| VOYAGER THERAPEUTICS INC CALL | VYGR | $2.0M | 413,642 | -0.13pp | 2q | -2.4%-$47.7K | |
| CONTINEUM THERAPEUTICS INC | CTNM | $2.0M | 119,733 | - | new | NEW | |
| BICYCLE THERAPEUTICS PLC | BCYC | $2.0M | 462,724 | -0.13pp | 2q | -2.9%-$58.1K | |
| VIRIDIAN THERAPEUTICS INC | VRDN | $1.8M | 100,000 | - | new | NEW | |
| MACROGENICS INC | MGNX | $1.7M | 374,403 | -0.08pp | 2q | -37.6%-$1.0M | |
| PROQR THRAPEUTICS N V | PRQR | $1.7M | 926,016 | +0.17pp | 7q | +414.2%+$1.4M | |
| ADMA BIOLOGICS INC CALL | ADMA | $1.7M | options only | - | new | OPTIONS | |
| SPRUCE BIOSCIENCES INC | SPRB | $1.6M | 30,000 | +0.09pp | 2q | +200.0%+$1.1M | |
| ARDELYX INC | ARDX | $1.5M | 303,025 | - | new | NEW | |
| CUE BIOPHARMA INC CALL | CUE | $1.5M | 48,369 | - | new | NEW | |
| MINERALYS THERAPEUTICS INC | MLYS | $1.5M | 56,347 | +0.07pp | 3q | +113.9%+$809.4K | |
| EYEPOINT INC CALL | EYPT | $1.5M | options only | -0.43pp | 2q | OPTIONS | |
| PROTHENA CORP PLC | PRTA | $1.5M | 149,482 | - | new | NEW | |
| PHATHOM PHARMACEUTICALS INC | PHAT | $1.4M | 129,950 | +0.07pp | 2q | +137.8%+$817.0K | |
| EVOLUS INC CALL | EOLS | $1.4M | options only | +0.09pp | 3q | OPTIONS | |
| SPYRE THERAPEUTICS INC | SYRE | $1.3M | 15,000 | - | new | NEW | |
| CORMEDIX INC PUT | CRMD | $1.3M | options only | -0.03pp | 4q | OPTIONS | |
| EDITAS MEDICINE INC CALL | EDIT | $1.3M | options only | - | new | OPTIONS | |
| EQUILLIUM INC | EQ | $1.3M | 400,282 | +0.01pp | 4q | -7.7%-$107.4K | |
| PYXIS ONCOLOGY INC CALL | PYXS | $1.2M | options only | - | new | OPTIONS | |
| XERIS BIOPHARMA HOLDINGS INC | XERS | $1.1M | 132,746 | flat | 4q | HELD | |
| PHARVARIS N V | PHVS | $1.0M | 29,321 | -0.01pp | 2q | HELD | |
| HARMONY BIOSCIENCES HLDGS IN | HRMY | $978.1K | 26,864 | -0.32pp | 4q | -71.1%-$2.4M | |
| CARTESIAN THERAPEUTICS INC | RNAC | $907.1K | 87,057 | - | new | NEW | |
| AQUESTIVE THERAPEUTICS INC CALL | AQST | $892.7K | options only | - | new | OPTIONS | |
| RIGEL PHARMACEUTICALS INC | RIGL | $892.6K | 22,816 | - | new | NEW | |
| ELICIO THERAPEUTICS INC CALL+PUT | ELTX | $829.3K | options only | - | new | OPTIONS | |
| PRECIGEN INC | PGEN | $771.2K | 135,293 | +0.06pp | 2q | +144.7%+$456.0K | |
| DEFINIUM THERAPEUTICS INC | DFTX | $726.8K | 15,451 | - | new | NEW | |
| PELTHOS THERAPEUTICS INC | PTHS | $700.1K | 24,773 | flat | 4q | HELD | |
| PEPGEN INC | PEPG | $671.9K | 373,284 | +0.04pp | 2q | +147.3%+$400.2K | |
| CG ONCOLOGY INC CALL | CGON | $518.7K | options only | - | new | OPTIONS | |
| ENLIVEN THERAPEUTICS INC | ELVN | $507.5K | 10,000 | +0.06pp | 2q | +3981.6%+$495.1K | |
| CONNECT BIOPHARMA HLDGS LTD | CNTB | $468.8K | 196,985 | -0.03pp | 2q | -1.8%-$8.8K | |
| LARIMAR THERAPEUTICS INC | LRMR | $447.2K | 146,637 | -0.07pp | 2q | -12.0%-$61.0K | |
| CELLECTAR BIOSCIENCES INC | CLRB | $384.6K | 138,341 | - | new | NEW | |
| FOGHORN THERAPEUTICS INC | FHTX | $326.5K | 66,908 | -0.02pp | 4q | -16.3%-$63.6K | |
| AYTU BIOPHARMA INC | AYTU | $319.4K | 148,546 | -0.12pp | 4q | -57.9%-$439.7K | |
| OCUGEN INC | OCGN | $306.0K | 200,000 | -0.12pp | 2q | HELD | |
| INOVIO PHARMACEUTICALS INC CALL | INO | $302.7K | options only | -0.15pp | 3q | OPTIONS | |
| UROGEN PHARMA LTD | URGN | $262.6K | 7,137 | -0.04pp | 7q | -69.2%-$589.5K | |
| HERON THERAPEUTICS INC | HRTX | $195.8K | 458,723 | - | new | NEW | |
| TALPHERA INC | TLPH | $158.2K | 153,563 | flat | 3q | HELD | |
| MONOPAR THERAPEUTICS INC | MNPR | $150.9K | 1,630 | flat | 2q | HELD | |
| LAKELAND INDS INC | LAKE | $150.8K | 14,108 | - | new | NEW | |
| UPSTREAM BIO INC | UPB | $132.1K | 19,093 | -0.02pp | 4q | -11.6%-$17.4K | |
| MEIRAGTX HLDGS PLC CALL | MGTX | $119.8K | 8,368 | - | new | NEW | |
| JATT II ACQUISITION CORP | $102.5K | 9,021 | - | new | NEW | ||
| KAILERA THERAPEUTICS INC | KLRA | $79.8K | 3,621 | - | new | NEW | |
| MANNKIND CORP | MNKD | $68.2K | 16,003 | -0.07pp | 6q | -91.4%-$726.8K | |
| ENTERA BIO LTD | ENTX | $41.2K | 23,260 | flat | 2q | HELD | |
| ARS PHARMACEUTICALS INC | SPRY | $38.9K | 4,860 | - | new | NEW | |
| APREA THERAPEUTICS INC | APRE | $36.0K | 44,907 | - | new | NEW | |
| TVARDI THERAPEUTICS INC | TVRD | $31.6K | 16,607 | - | new | NEW | |
| VISTAGEN THERAPEUTICS INC CALL | VTGN | $13.0K | options only | -0.01pp | 7q | OPTIONS | |
| NEXTCURE INC | NXTC | $12.4K | 7,742 | - | new | NEW | |
| ATYR PHARMA INC PUT | ATYR | $7.5K | options only | flat | 6q | OPTIONS | |
| JADE BIOSCIENCES INC PUT | JBIO | $3.2K | options only | flat | 4q | OPTIONS | |
| ERASCA INC CALL | ERAS | $1.8K | options only | - | new | OPTIONS |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $756.7M | 95.6% |
| Healthcare Services | $15.7M | 2.0% |
| Other sectors | $150.8K | 0.0% |
| Not classified | $18.8M | 2.4% |
What the disclosed book did
This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.
| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q3 2025 | +8.8% | +7.8% | +1.0% | 66% |
| Q1 2025 | -5.4% | -4.6% | -0.8% | 65% |
Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $791.3M | 116 | 43 | 21 | 32 | 38 | 50.4% | 45 |
| Q1 2026 | $587.7M | 111 | 44 | 24 | 19 | 52 | 50.5% | 45 |
| Q4 2025 | $580.5M | 119 | 46 | 16 | 23 | 33 | 49.4% | 48 |
| Q3 2025 | $391.0M | 106 | 53 | 6 | 22 | 22 | 39.1% | 45 |
| Q2 2025 | $328.2M | 75 | 23 | 16 | 15 | 20 | 53.7% | 45 |
| Q1 2025 | $383.3M | 72 | 31 | 17 | 10 | 45 | 67.5% | 45 |
| Q4 2024 | $233.1M | 86 | 0 | 0 | 0 | 0 | 51.8% | 45 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.